Barrett, David M <br/><br/>
Toxicity management for patients receiving novel T-cell engaging therapies.  [electronic resource] 

 -  Current opinion in pediatrics  Feb 2014 
 - 43-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1531-698X 
<br/><br/><label>Standard No.: </label>10.1097/MOP.0000000000000043  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Bispecific--adverse effects<br/>Antigens, CD19--immunology<br/>Child<br/>Cytokines--biosynthesis<br/>Humans<br/>Immune System Diseases--immunology<br/>Immunotherapy--adverse effects<br/>Lymphocyte Activation--immunology<br/>Lymphohistiocytosis, Hemophagocytic--immunology<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--immunology<br/>Receptors, Antigen, T-Cell--immunology<br/>Syndrome<br/>T-Lymphocytes--immunology